Consensus Eledon Pharmaceuticals, Inc.

Equities

ELDN

US28617K1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
3.02 ^USD	+7.86%		+30.74%	+67.78%

May. 07	Eledon Pharmaceuticals, Inc. Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection	CI
May. 06	Eledon Pharmaceuticals, Inc. announced that it expects to receive $49.99901 million in funding	CI

Evolution of the average Target Price on Eledon Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

9ea051e657e7ab123.UHvo7P3EX2hqPS9rX11pjw5gMhjHfeFxB7KDmo6vyVA.KEyJr76hOTkeXGNGLQcqxH4td06vC4YyQfvV18jFvgokFa-EkZczEh10Gw~f1cd6a81c347a94282e08123db7ea7b3

Analyst Recommendations on Eledon Pharmaceuticals, Inc.

Noble Capital Initiates Coverage on Eledon Pharmaceuticals with Outperform Rating, $10 Price Target	23-09-27	MT
SVB Securities LLC Adjusts Price Target for Eledon Pharmaceuticals to $26 From $33, Reiterates Outperform Rating	22-06-01	MT
HC Wainwright Adjusts Eledon Pharmaceuticals' Price Target to $25 From $35, Keeps Buy Rating	21-11-24	MT
ELEDON PHARMACEUTICALS : SVB Leerink Adjusts Price Target on Eledon Pharmaceuticals to $33 From $34, Maintains Outperform Rating	21-04-27	MT
ELEDON PHARMACEUTICALS : Cantor Fitzgerald Starts Eledon Pharmaceuticals at Overweight With $25 Price Target	21-03-23	MT
ELEDON PHARMACEUTICALS : SVB Leerink Starts Eledon Pharmaceuticals at Outperform With $34 Price Target	21-02-08	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.02 USD

Average target price

14 USD

Spread / Average Target

+363.58%

High Price Target

28 USD

Spread / Highest target

+827.15%

Low Price Target

7 USD

Spread / Lowest Target

+131.79%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Eledon Pharmaceuticals, Inc.

Noble Capital
SVB Securities LLC
HC Wainwright
SVB Leerink
Cantor Fitzgerald

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar